Abstract
Nosocomial infections of both patients and healthcare workers (HCWs) in hospitals may play an important part in the overall dynamics of a viral pandemic, as evidenced by the recent COVID-19 experience. A strategy to control this risk consists in dedicating some hospitals to the care of infected patients only, with HCWs alternating between shifts of continuous stay within these hospitals and periods of isolation. This strategy has been implemented locally in various settings and generalized in Egypt. Here, using a mathematical model coupling hospitals and community, we assess the impact of this strategy on overall epidemic dynamics. We find that quarantine hospitals may significantly reduce the number of cumulative cases, as well as the peak incidence. These benefits are highest when effective control strategies are in place in the community and symptomatic HCWs comply with self-isolation recommendations. Our results, which are robust to variations in assumed biological characteristics of the virus, suggest that the quarantine hospital strategy should be considered in future pandemic contexts to best protect the entire population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by INSERM-ANRS (France Recherche Nord and Sud Sida-HIV Hepatites, grant number ANRS-COV-19).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.